http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Aug 2026 16:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26890775.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 4, 2026, pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> The Option Awards have an exercise price of $25.50 per share, equal to the closing price of the Company’s http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26890775.html Fri, 07 Aug 2026 16:00:00 -0400 FTH O.49824919 http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26890775.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 4, 2026, pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> The Option Awards have an exercise price of $25.50 per share, equal to the closing price of the Company’s http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26890775.html Fri, 07 Aug 2026 16:00:00 -0400 FTH O.49824919 http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26890775.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 4, 2026, pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> The Option Awards have an exercise price of $25.50 per share, equal to the closing price of the Company’s http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26890775.html Fri, 07 Aug 2026 16:00:00 -0400 FTH O.49824919 http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26890775.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 4, 2026, pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> The Option Awards have an exercise price of $25.50 per share, equal to the closing price of the Company’s http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26890775.html Fri, 07 Aug 2026 16:00:00 -0400 FTH O.49824919 http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html <p> <i>— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8</i> </p><p> <i>— These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201)</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html Fri, 07 Aug 2026 07:30:00 -0400 A.50217011 FTH O.49824919 O.76446908 http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html <p> <i>— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8</i> </p><p> <i>— These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201)</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html Fri, 07 Aug 2026 07:30:00 -0400 A.50217011 FTH O.49824919 O.76446908 http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html <p> <i>— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8</i> </p><p> <i>— These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201)</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html Fri, 07 Aug 2026 07:30:00 -0400 A.50217011 FTH O.49824919 O.76446908 http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html <p> <i>— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8</i> </p><p> <i>— These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201)</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html Fri, 07 Aug 2026 07:30:00 -0400 A.50217011 FTH O.49824919 O.76446908 http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html <p> <i>— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8</i> </p><p> <i>— These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201)</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html Fri, 07 Aug 2026 07:30:00 -0400 A.50217011 FTH O.49824919 O.76446908 http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html <p> <i>— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8</i> </p><p> <i>— These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201)</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html Fri, 07 Aug 2026 07:30:00 -0400 A.50217011 FTH O.49824919 O.76446908 http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html <p> <i>— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8</i> </p><p> <i>— These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201)</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html Fri, 07 Aug 2026 07:30:00 -0400 A.50217011 FTH O.49824919 O.76446908 http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html <p> <i>— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8</i> </p><p> <i>— These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201)</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+to+Present+PKPD+Modeling+That+Informed+PIKTOR+Dose+Selection+in+Ongoing+FTH-PIK-201+Trial+at+Upcoming+Scientific+Conference/26887512.html Fri, 07 Aug 2026 07:30:00 -0400 A.50217011 FTH O.49824919 O.76446908 http://www.streetinsider.com/Earnings/Faeth+Therapeutics%2C+Inc.+%28FTH%29+Tops+Q2+EPS+by+132c/26862241.html <p>Faeth Therapeutics, Inc. (NASDAQ: FTH) reported Q2 EPS of ($2.84), $1.32 better than the analyst estimate of ($4.16).</p><p>For earnings history and earnings-related data on Faeth Therapeutics, Inc. (FTH) <a href="http://www.streetinsider.com/ec_earnings.php?q=FTH">click here</a>.</p> http://www.streetinsider.com/Earnings/Faeth+Therapeutics%2C+Inc.+%28FTH%29+Tops+Q2+EPS+by+132c/26862241.html Tue, 04 Aug 2026 08:22:12 -0400 FTH http://www.streetinsider.com/New+Coverage/Jones+Trading+Starts+Faeth+Therapeutics+%28FTH%29+at+Buy/26862052.html <p>Jones Trading analyst Matt Murray initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating and a price target of $55.00.</p><p>For an analyst ratings summary and ratings history on Faeth Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=FTH">click here</a>. For more ratings news on Faeth Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FTH&amp;type=analyst">click here</a>.</p><p>Shares of Faeth Therapeutics closed at $27.34 yesterday.</p> http://www.streetinsider.com/New+Coverage/Jones+Trading+Starts+Faeth+Therapeutics+%28FTH%29+at+Buy/26862052.html Tue, 04 Aug 2026 08:03:39 -0400 FTH http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Faeth+Therapeutics%2C+Inc.++For%3A+Jun+30/26861698.html si-local-file:///var/storage/secattach/20260804/26861698.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Faeth+Therapeutics%2C+Inc.++For%3A+Jun+30/26861698.html Tue, 04 Aug 2026 07:41:00 -0400 FTH O.49824919 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Faeth+Therapeutics%2C+Inc.++For%3A+Jun+30/26861698.html si-local-file:///var/storage/secattach/20260804/26861698.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Faeth+Therapeutics%2C+Inc.++For%3A+Jun+30/26861698.html Tue, 04 Aug 2026 07:41:00 -0400 FTH O.49824919 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Faeth+Therapeutics%2C+Inc.++For%3A+Aug+04/26861697.html si-local-file:///var/storage/secattach/20260804/26861697.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Faeth+Therapeutics%2C+Inc.++For%3A+Aug+04/26861697.html Tue, 04 Aug 2026 07:40:00 -0400 FTH O.49824919 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Faeth+Therapeutics%2C+Inc.++For%3A+Aug+04/26861697.html si-local-file:///var/storage/secattach/20260804/26861697.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Faeth+Therapeutics%2C+Inc.++For%3A+Aug+04/26861697.html Tue, 04 Aug 2026 07:40:00 -0400 FTH O.49824919 http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html <p> <i>— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end</i> </p><p> <i>— First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer</i> </p><p> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock began trading under the ticker symbol “FTH” on June 16, 2026</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. </p><p> “Our combination with Sensei Biotherapeutics http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html Tue, 04 Aug 2026 07:30:00 -0400 A.06822034 FTH O.20026344 O.49824919 http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html <p> <i>— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end</i> </p><p> <i>— First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer</i> </p><p> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock began trading under the ticker symbol “FTH” on June 16, 2026</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. </p><p> “Our combination with Sensei Biotherapeutics http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html Tue, 04 Aug 2026 07:30:00 -0400 A.06822034 FTH O.20026344 O.49824919 http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html <p> <i>— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end</i> </p><p> <i>— First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer</i> </p><p> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock began trading under the ticker symbol “FTH” on June 16, 2026</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. </p><p> “Our combination with Sensei Biotherapeutics http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html Tue, 04 Aug 2026 07:30:00 -0400 A.06822034 FTH O.20026344 O.49824919 http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html <p> <i>— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end</i> </p><p> <i>— First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer</i> </p><p> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock began trading under the ticker symbol “FTH” on June 16, 2026</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. </p><p> “Our combination with Sensei Biotherapeutics http://www.streetinsider.com/Press+Releases/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html Tue, 04 Aug 2026 07:30:00 -0400 A.06822034 FTH O.20026344 O.49824919 http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html <p> <i>— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end</i> </p><p> <i>— First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer</i> </p><p> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock began trading under the ticker symbol “FTH” on June 16, 2026</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. </p><p> “Our combination with Sensei Biotherapeutics http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html Tue, 04 Aug 2026 07:30:00 -0400 A.06822034 FTH O.20026344 O.49824919 http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html <p> <i>— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end</i> </p><p> <i>— First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer</i> </p><p> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock began trading under the ticker symbol “FTH” on June 16, 2026</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. </p><p> “Our combination with Sensei Biotherapeutics http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html Tue, 04 Aug 2026 07:30:00 -0400 A.06822034 FTH O.20026344 O.49824919 http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html <p> <i>— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end</i> </p><p> <i>— First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer</i> </p><p> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock began trading under the ticker symbol “FTH” on June 16, 2026</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. </p><p> “Our combination with Sensei Biotherapeutics http://www.streetinsider.com/Business+Wire/Faeth+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Updates/26861588.html Tue, 04 Aug 2026 07:30:00 -0400 A.06822034 FTH O.20026344 O.49824919